IFFIm program celebrates first year with $912M donations to immunization projects worldwide

3 December 2007

The GAVI Alliance, which distributes funds raised by the International Finance Facility for Immunization (IFFIm) has announced that, in its first year, the scheme has resulted in $912.0 million being distributed to developing countries, to provide for the immunization programs or the infrastructure to enable vaccination to go ahead. Julian Lob-Levyt, the GAVI Alliance's executive secretary, said: "IFFIm support has doubled the amount of money GAVI has been able to allocate to its immunization and health system-strengthening programs."

The World Bank manages the IFFIm's finances, funding strategy, and its implementation in the capital markets. Of the $912.0 million being given to countries in 2007:

- $181.0 million is being spent on securing supply of the combination pentavalent vaccine for children against diptheria, pertussis, tetanus, hepatitis B and Haemophilus influenzae type b (Hib), a cause of severe infections including meningitis and pneumonia;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight